**Supplementary Table 1**: **Association between PD-L1 score and clinical characteristics, for each antibody**

|  |  |  |
| --- | --- | --- |
| **Characteristics** | **E1L3N antibody****(*n* = 32)** | **5H1 antibody** **(*n* = 30)** |
| Positive score (*n* = 6)*n* (%) | Negative score (*n* = 26)*n* (%) | p-value\* | Positive score(*n* = 3)*n* (%) | Negative score(*n* = 27) *n* (%) | p-value\* |
| **Age median 51.1 years**≤ median > median | 4 (66.7)2 (33.3) | 12 (46.2)14 (53.8) | 0.36 | 1 (33.3)2 (66.6) | 14 (51.9)13 (48.5) | 0.74 |
| **Gender**MaleFemale | 5 (83.3)1 (16.7) | 23 (88.5)3 (11.5) | 0.93 | 3 (100)0  | 3 (11.1)24 (88.9) | 1 |
| **Smoking status**NeverCurrent/former | 06 (100) | 1 (3.8)25 (96.2) | 0.21 | 03 (100) | 1 (3.7)26 (96.3) | 0.40 |
| **Histology**AdenocarcinomaSquamous cell Large cell | 5 (83.3)1 (16.7)0 | 21 (80.8)4 (15.4)1 (3.8) | 0.79 | 3 (100)0 0  | 21 (77.8)4 (14.8)2 (7.4) | 0.69 |
| **TNM stage**IIIIIIIV | 1 (16.7)03 (50)2 (33.3) | 2 (7.8)4 (15.6)11 (42.3)11 (42.3) | 0.78 | 0 0 1 (33.3)2 (66.6) | 2 (7.4)4 (14.8)11 (40.7)10 (37.0) | 0.75 |

\*: Mann-Withney U-test; TNM: tumor node metastasis; PD-L1: programmed cell death protein 1 to PD ligand 1; HIV: human immunodeficiency virus

**Supplementary figure 1: Flow chart of tumors from HIV-positive population.**

PD-L1: programmed cell death protein 1 to PD ligand 1.



**Supplementary figure 2: Overall survival of HIV-positive patients according to PD-L1 score (positive or negative) and to antibody (A: clone E1L3N; B: clone 5H1).** Analysis were performed using a Cox survival analysis.

